Compare PKE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | ESPR |
|---|---|---|
| Founded | 1954 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 635.0M | 731.9M |
| IPO Year | 1994 | 2013 |
| Metric | PKE | ESPR |
|---|---|---|
| Price | $35.91 | $3.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 266.9K | ★ 9.1M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | ★ 93.10 | 60.71 |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | $59.98 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $13.53 | $0.95 |
| 52 Week High | $38.20 | $4.18 |
| Indicator | PKE | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 69.30 |
| Support Level | $31.27 | $3.11 |
| Resistance Level | $38.20 | $3.18 |
| Average True Range (ATR) | 2.10 | 0.01 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 71.79 | 83.33 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.